Cynosure Company Profile (NASDAQ:CYNO)

About Cynosure (NASDAQ:CYNO)

Cynosure logoCynosure, Inc. develops, manufactures and markets aesthetic treatment systems that enable plastic surgeons, dermatologists and other medical practitioners to perform non-invasive and minimally invasive procedures to remove hair, treat vascular and benign pigmented lesions, remove multi-colored tattoos, revitalize the skin, reduce fat through laser lipolysis, reduce cellulite, clear nails infected by toe fungus, ablate sweat glands and improve women's health. The Company also markets radiofrequency (RF), energy-sourced medical devices for surgical applications, such as facial plastic and general surgery, gynecology, ear, nose, and throat procedures, ophthalmology, oral and maxillofacial surgery, podiatry and proctology. The Company sells its products globally under the Cynosure, Palomar, ConBio and Ellman brand names. Its product portfolio includes single energy source systems, as well as workstations that incorporate two or more different types of lasers or light-based technologies.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Advanced Medical Equipment & Technology
  • Sub-Industry: Health Care Equipment
  • Symbol: NASDAQ:CYNO
  • CUSIP: 23257720
  • Web: www.cynosure.com/
Average Prices:
  • 50 Day Moving Avg: $62.47
  • 200 Day Moving Avg: $50.89
  • 52 Week Range: $39.90 - $66.65
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: 32.50
  • P/E Growth: 0.00
Profitability:
  • Net Margins: 0.70%
  • Return on Equity: 0.75%
  • Return on Assets: 0.59%
Debt:
  • Debt-to-Equity Ratio: 0.04%
  • Current Ratio: 3.28%
  • Quick Ratio: 2.54%
Misc:
  • Average Volume: 1.17 million shs.
  • Beta: 1.65
 

Frequently Asked Questions for Cynosure (NASDAQ:CYNO)

What is Cynosure's stock symbol?

Cynosure trades on the NASDAQ under the ticker symbol "CYNO."

How were Cynosure's earnings last quarter?

Cynosure, Inc. (NASDAQ:CYNO) released its quarterly earnings data on Tuesday, July, 26th. The company reported $0.36 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.29 by $0.07. The firm had revenue of $110.30 million for the quarter, compared to analyst estimates of $101.31 million. Cynosure had a return on equity of 0.75% and a net margin of 0.70%. The business's revenue for the quarter was up 31.8% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.30 earnings per share. View Cynosure's Earnings History.

Where is Cynosure's stock going? Where will Cynosure's stock price be in 2017?

7 equities research analysts have issued 12 month price targets for Cynosure's shares. Their forecasts range from $40.00 to $66.00. On average, they expect Cynosure's share price to reach $58.33 in the next twelve months. View Analyst Ratings for Cynosure.

Who are some of Cynosure's key competitors?

How do I buy Cynosure stock?

Shares of Cynosure can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Cynosure's stock price today?

One share of Cynosure stock can currently be purchased for approximately $65.97.


MarketBeat Community Rating for Cynosure (NASDAQ CYNO)
Community Ranking:  3.3 out of 5 (star star star)
Outperform Votes:  211 (Vote Outperform)
Underperform Votes:  107 (Vote Underperform)
Total Votes:  318
MarketBeat's community ratings are surveys of what our community members think about Cynosure and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Cynosure (NASDAQ:CYNO) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 3 Hold Ratings, 4 Buy Ratings
Consensus Rating:Buy (Score: 2.57)
Consensus Price Target: $58.33 (11.58% downside)

Analysts' Ratings History for Cynosure (NASDAQ:CYNO)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
3/28/2017AegisReiterated RatingHold$66.00N/AView Rating Details
2/16/2017Northland SecuritiesReiterated RatingOutperform$60.00N/AView Rating Details
2/14/2017Northcoast ResearchUpgradeSell -> NeutralN/AView Rating Details
2/14/2017Maxim GroupDowngradeBuy -> Hold$66.00N/AView Rating Details
10/28/2016Leerink SwannReiterated RatingOutperform$63.00 -> $60.00N/AView Rating Details
10/26/2016Stifel NicolausReiterated RatingBuy$62.00 -> $58.00N/AView Rating Details
10/24/2016Brean CapitalReiterated RatingBuyN/AView Rating Details
(Data available from 9/21/2015 forward)

Earnings

Earnings History for Cynosure (NASDAQ:CYNO)
Earnings by Quarter for Cynosure (NASDAQ:CYNO)
Earnings History by Quarter for Cynosure (NASDAQ CYNO)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/7/2017Q416$0.41$0.44$119.97 million$122.10 millionViewListenView Earnings Details
10/25/2016Q316$0.28$0.29$101.11 million$106.40 millionViewListenView Earnings Details
7/26/2016Q216$0.29$0.36$101.31 million$110.30 millionViewListenView Earnings Details
4/26/2016Q116$0.14$0.19$85.78 million$94.70 millionViewListenView Earnings Details
2/9/2016Q415$0.36$0.42$95.01 million$102.40 millionViewListenView Earnings Details
10/27/2015Q315$0.18$0.21$76.68 million$78.40 millionViewListenView Earnings Details
7/28/2015Q215$0.27$0.30$82.71 million$83.70 millionViewListenView Earnings Details
5/5/2015Q1$0.17$0.15$70.87 million$74.90 millionViewListenView Earnings Details
2/10/2015Q414$0.39$0.36$83.01 million$86.30 millionViewListenView Earnings Details
10/28/2014Q314$0.24$0.25$69.94 million$71.50 millionViewListenView Earnings Details
7/29/2014Q214$0.30$0.32$71.15 million$72.60 millionViewListenView Earnings Details
5/6/2014Q1$0.23$0.19$64.70 million$62.00 millionViewListenView Earnings Details
2/12/2014Q413$0.19$0.39$67.80 million$74.50 millionViewListenView Earnings Details
10/29/2013Q313$0.19$0.23$61.60 million$60.70 millionViewListenView Earnings Details
7/31/2013Q2 2013$0.20$0.29$46.96 million$50.09 millionViewListenView Earnings Details
4/30/2013Q1 2013$0.13$0.12$38.51 million$10.70 millionViewListenView Earnings Details
2/12/2013Q4 2012$0.23$0.27$40.98 million$47.70 millionViewListenView Earnings Details
10/23/2012$0.12$0.25ViewN/AView Earnings Details
7/24/2012$0.12$0.20ViewN/AView Earnings Details
5/1/2012($0.02)$0.06ViewN/AView Earnings Details
2/14/2012$0.05$0.08ViewN/AView Earnings Details
10/25/2011$0.04($0.06)ViewN/AView Earnings Details
5/3/2011($0.05)($0.15)ViewN/AView Earnings Details
2/15/2011($0.03)($0.06)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Cynosure (NASDAQ:CYNO)
2017 EPS Consensus Estimate: $1.63
2018 EPS Consensus Estimate: $2.02
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20173$0.23$0.26$0.24
Q2 20173$0.40$0.44$0.43
Q3 20173$0.38$0.42$0.40
Q4 20173$0.51$0.61$0.57
Q1 20181$0.34$0.34$0.34
Q2 20181$0.51$0.51$0.51
Q3 20181$0.50$0.50$0.50
Q4 20181$0.67$0.67$0.67
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Cynosure (NASDAQ:CYNO)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Cynosure (NASDAQ:CYNO)
Insider Ownership Percentage: 2.90%
Insider Trades by Quarter for Cynosure (NASDAQ:CYNO)
Institutional Ownership by Quarter for Cynosure (NASDAQ:CYNO)
Insider Trades by Quarter for Cynosure (NASDAQ:CYNO)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
11/22/2016Douglas J DelaneyVPSell7,875$45.00$354,375.00View SEC Filing  
11/22/2016Michael R DavinChairmanSell16,284$45.00$732,780.00View SEC Filing  
8/30/2016Brian M BarefootDirectorSell21,000$51.66$1,084,860.00View SEC Filing  
8/15/2016Michael R DavinChairmanSell12,062$53.35$643,507.70View SEC Filing  
8/15/2016Timothy W BakerCFOSell5,834$53.35$311,243.90View SEC Filing  
8/11/2016Michael R DavinChairmanSell4,222$53.18$224,525.96View SEC Filing  
8/11/2016Timothy W BakerCFOSell2,041$53.19$108,560.79View SEC Filing  
5/13/2016Douglas J DelaneyVPSell12,299$46.60$573,133.40View SEC Filing  
5/13/2016Michael R DavinCEOSell26,271$46.59$1,223,965.89View SEC Filing  
5/13/2016Timothy W BakerCFOSell12,451$46.60$580,216.60View SEC Filing  
4/18/2016Douglas J DelaneyVPSell15,890$45.01$715,208.90View SEC Filing  
4/18/2016Michael R DavinCEOSell74,729$45.31$3,385,970.99View SEC Filing  
4/18/2016Timothy W BakerCFOSell14,008$45.02$630,640.16View SEC Filing  
4/14/2016Douglas J DelaneyVPSell24,488$45.02$1,102,449.76View SEC Filing  
4/14/2016Michael R DavinCEOSell61,377$45.01$2,762,578.77View SEC Filing  
4/14/2016Timothy W BakerCFOSell39,857$45.02$1,794,362.14View SEC Filing  
4/13/2016Michael R DavinCEOSell72$45.00$3,240.00View SEC Filing  
4/6/2016Douglas J DelaneyVPSell4,408$45.08$198,712.64View SEC Filing  
4/6/2016Michael R DavinCEOSell4,869$45.11$219,640.59View SEC Filing  
4/6/2016Timothy W BakerCFOSell4,413$45.08$198,938.04View SEC Filing  
4/4/2016Douglas J DelaneyVPSell66,626$45.47$3,029,484.22View SEC Filing  
4/4/2016Michael R DavinCEOSell66,259$45.61$3,022,072.99View SEC Filing  
4/4/2016Timothy W BakerCFOSell53,297$45.60$2,430,343.20View SEC Filing  
12/31/2015Michael R. DavinCEOSell200$45.00$9,000.00View SEC Filing  
12/31/2015Timothy W. BakerCFOSell100$45.00$4,500.00View SEC Filing  
6/1/2015Ettore V BiagioniDirectorSell24,000$36.25$870,000.00View SEC Filing  
5/20/2015Douglas J DelaneyVPSell89,000$38.01$3,382,890.00View SEC Filing  
5/20/2015Michael R DavinCEOSell151,000$38.07$5,748,570.00View SEC Filing  
4/23/2015Michael R DavinCEOSell6,991$33.04$230,982.64View SEC Filing  
4/10/2015Michael R DavinCEOSell44,677$33.01$1,474,787.77View SEC Filing  
4/9/2015Douglas J DelaneyVPSell28,335$33.01$935,338.35View SEC Filing  
4/9/2015Michael R DavinCEOSell70,000$32.00$2,240,000.00View SEC Filing  
4/8/2015Douglas J DelaneyVPSell45,000$32.00$1,440,000.00View SEC Filing  
1/9/2015Ettore V BiagioniDirectorSell12,000$30.09$361,080.00View SEC Filing  
12/2/2014Ettore V BiagioniDirectorSell2,500$28.00$70,000.00View SEC Filing  
11/24/2014Ettore V BiagioniDirectorSell5,000$27.28$136,400.00View SEC Filing  
11/5/2013Marina HatsopoulosDirectorBuy3,000$22.60$67,800.00View SEC Filing  
9/5/2012Douglas J DelaneyVPSell16,904$27.65$467,395.60View SEC Filing  
9/5/2012Michael R DavinCEOSell16,770$27.65$463,690.50View SEC Filing  
9/5/2012Timothy W BakerCFOSell16,854$27.65$466,013.10View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Cynosure (NASDAQ:CYNO)
Latest Headlines for Cynosure (NASDAQ:CYNO)
Source:
DateHeadline
thestreet.com logoTrump's Pick for Federal Reserve's Top Regulator Just Won This Battle
www.thestreet.com - September 8 at 6:07 PM
nasdaq.com logoCutera Strengthens Leadership Team with Two Key Executive Appointments - Nasdaq
www.nasdaq.com - August 21 at 10:26 PM
businesswire.com logoGlobal Aesthetic Laser Market 2017-2023 - Leading Companies Cynosure, Lumenis, Cutera, Alma Lasers & Sciton - Research and Markets
www.businesswire.com - August 19 at 4:57 PM
businesswire.com logoGlobal Aesthetic Laser Market 2017-2023 - Leading Companies ... - Business Wire (press release)
www.businesswire.com - August 18 at 5:44 PM
americanbankingnews.com logoAnalyzing Derma Sciences (DSCI) & Cynosure (CYNO)
www.americanbankingnews.com - August 3 at 8:29 AM
seekingalpha.com logoHologic (HOLX) Q3 2017 Results - Earnings Call Transcript
seekingalpha.com - August 2 at 11:37 PM
bizjournals.com logoHologic Announces Financial Results for Third Quarter of Fiscal 2017
www.bizjournals.com - August 2 at 6:37 PM
bloomberg.com logoTrump's Wall Street Watchdogs to Shed Millions Invested in Banks - Bloomberg
www.bloomberg.com - July 25 at 5:42 PM
nasdaq.com logoWhat's in the Offing for Hologic (HOLX) in Q3 Earnings? - Nasdaq
www.nasdaq.com - July 24 at 10:46 AM
globenewswire.com logoMedical Aesthetics Market to Reach $19.4 Billion by 2023: P&S Market Research
globenewswire.com - July 19 at 11:56 PM
seekingalpha.com logoHologic: Growth Cheaply Priced - Seeking Alpha
seekingalpha.com - July 16 at 9:42 AM
bloomberg.com logoRevolving Door Spins Ex-Carlyle Deal-Maker Into Key Fed Role
www.bloomberg.com - July 12 at 11:27 PM
nytimes.com logoTrump's Fed Nominee Has History of Benefiting From Bailouts - New York Times
www.nytimes.com - July 12 at 6:24 PM
americanbankingnews.com logoCynosure, Inc. (CYNO) Given Consensus Rating of "Hold" by Brokerages
www.americanbankingnews.com - June 23 at 10:58 PM
prnewswire.com logoHologic Receives Expanded FDA 510(k) Clearance to Market Cynosure's SculpSure ...
www.prnewswire.com - June 15 at 6:33 PM
finanznachrichten.de logoGlobal Cellulite Treatment Market - Industry Forecast to 2025 - Analysis By Treatment, End User & Geography - Research and Markets
www.finanznachrichten.de - June 8 at 5:39 PM
benzinga.com logoGlobal Anti-Aging Market Size & Trends Will Reach $216.52 Billion by 2021: Zion Market Research
www.benzinga.com - June 5 at 11:54 AM
americanbankingnews.com logoCynosure, Inc. (CYNO) Given Consensus Rating of "Hold" by Analysts
www.americanbankingnews.com - May 29 at 9:06 PM
finanznachrichten.de logoGlobal Medical Aesthetics Market to Reach $13 Billion by 2021 - Analysis By Product, End User & Region - Research and Markets
www.finanznachrichten.de - May 29 at 4:45 PM
bizjournals.com logoAsia-Pacific Aesthetic Lasers and Energy Devices Market Outlook to 2023
www.bizjournals.com - May 16 at 4:39 PM
prnewswire.com logoMedical Aesthetic Devices Market - Middle East and North Africa Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024
www.prnewswire.com - May 11 at 10:18 PM
americanbankingnews.com logoCynosure (CYNO) Earning Somewhat Favorable News Coverage, Analysis Finds
www.americanbankingnews.com - May 3 at 3:28 PM
marketwatch.com logoAesthetics Combination Therapy Market Revenues to Reach US$ 3.69 Bn by 2024 - Persistence Market Research
www.marketwatch.com - May 3 at 8:46 AM
americanbankingnews.com logoCynosure, Inc. (CYNO) Receives Average Rating of "Hold" from Brokerages
www.americanbankingnews.com - May 2 at 10:48 PM
americanbankingnews.com logoCynosure (CYNO) Receives Media Impact Rating of 0.12
www.americanbankingnews.com - April 29 at 9:35 PM
bizjournals.com logoLiposuction Devices - Global Market Outlook (2016-2022)
www.bizjournals.com - April 27 at 5:10 PM
americanbankingnews.com logoSomewhat Negative News Coverage Very Unlikely to Impact Cynosure (CYNO) Stock Price
www.americanbankingnews.com - April 26 at 1:52 PM
americanbankingnews.com logoCynosure (CYNO) Earning Somewhat Positive News Coverage, Analysis Finds
www.americanbankingnews.com - April 23 at 2:09 PM
americanbankingnews.com logoCynosure, Inc. (CYNO) to Release Earnings on Monday
www.americanbankingnews.com - April 21 at 11:26 PM
americanbankingnews.com logoCynosure (CYNO) Receiving Positive Media Coverage, Report Shows
www.americanbankingnews.com - April 20 at 8:59 PM
bloomberg.com logoTrump to Nominate Quarles for Fed's Top Regulatory Post, Source Says
www.bloomberg.com - April 18 at 12:07 PM
americanbankingnews.com logoSomewhat Negative Press Coverage Likely to Impact Cynosure (CYNO) Stock Price
www.americanbankingnews.com - April 15 at 2:13 PM
prnewswire.com logoSouth Korea Aesthetic Lasers and Energy Devices Market Outlook to 2023
www.prnewswire.com - April 11 at 4:29 PM
bizjournals.com logoGermany Aesthetic Lasers and Energy Devices Market Outlook to 2023
www.bizjournals.com - April 10 at 4:30 PM
americanbankingnews.com logoCynosure, Inc. (CYNO) Receives Average Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - April 5 at 5:19 PM
americanbankingnews.com logoAegis Reiterates "Hold" Rating for Cynosure, Inc. (CYNO)
www.americanbankingnews.com - March 28 at 11:23 AM
americanbankingnews.com logoCynosure, Inc. (CYNO) Short Interest Down 29.3% in March
www.americanbankingnews.com - March 28 at 8:26 AM
streetinsider.com logoForm 4 CYNOSURE INC For: Mar 22 Filed by: Hatsopoulos Marina - StreetInsider.com
www.streetinsider.com - March 25 at 11:01 AM
streetinsider.com logoForm 4 CYNOSURE INC For: Mar 22 Filed by: Hatsopoulos Marina
www.streetinsider.com - March 24 at 9:55 PM
streetinsider.com logoForm SC 14D9/A CYNOSURE INC Filed by: CYNOSURE INC
www.streetinsider.com - March 24 at 4:53 PM
marketwatch.com logoDermatology Devices Market Worth $25 Billion by 2025 | CAGR: 12.7%: Grand View Research, Inc.
www.marketwatch.com - March 23 at 5:11 PM
biz.yahoo.com logoCYNOSURE INC Files SEC form 8-K, Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure t
biz.yahoo.com - March 23 at 5:11 PM
finance.yahoo.com logoMRLB U.S. Sales Jump 38% As Aesthetic Market Heats Up
finance.yahoo.com - March 22 at 4:46 PM
americanbankingnews.com logoCynosure, Inc. (CYNO) Downgraded by Aegis to Hold
www.americanbankingnews.com - March 21 at 7:10 AM
americanbankingnews.com logoAegis Lowers Cynosure, Inc. (CYNO) to Hold
www.americanbankingnews.com - March 18 at 8:45 AM
americanbankingnews.com logoCynosure, Inc. (CYNO) Short Interest Update
www.americanbankingnews.com - March 11 at 7:33 AM
americanbankingnews.com logoCynosure, Inc. (CYNO) Given Average Rating of “Hold” by Analysts
www.americanbankingnews.com - March 10 at 12:38 PM
finance.yahoo.com logoScar Treatment Market Worth $34.5 Billion by 2025 | Growth Rate: 9.7%: Grand View Research, Inc.
finance.yahoo.com - March 8 at 5:23 PM
finance.yahoo.com logoCYNOSURE INC Financials
finance.yahoo.com - March 4 at 5:02 PM
streetinsider.com logoForm SC 14D9/A CYNOSURE INC Filed by: CYNOSURE INC - StreetInsider.com
www.streetinsider.com - March 4 at 2:49 AM

Social

Chart

Cynosure (CYNO) Chart for Thursday, September, 21, 2017

This page was last updated on 9/21/2017 by MarketBeat.com Staff